In an interview, synthetic biologist Peter Carr explains research on synthetic cells, their potential benefits and hazards, ...

Q2 of 2026 started with a white-hot rally in the stock market, recovering its losses from the first quarter and setting ...

Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel ...

Compass Pathways (CMPS) stock rises as the company posts new late-stage trial data for its psychedelic therapy COMP360 ...

After spending nearly Rs 6,800 crore and more than two decades, Wockhardt has achieved what no Indian pharmaceutical company ...

The infrastructure moment for AI-driven drug discovery continues to accelerate, with billion-dollar investments flowing into ...

The notable startup funding rounds for the week ending 7/4/26 featuring funding details for Qolab, Straiker, Higharc, and ...

I suspect that the vast majority of people who are living in areas where the fungus resides in the soil are completely ...

Modern biopharma firms are adapting their R&D investment strategies in response to challenges such as the impending $300 ...

A new poll shows Mike Minogue with a commanding lead in the GOP governor primary. But the real battle may be the escalating ...

A UCLA study has identified a hidden Achilles' heel in aggressive small cell cancers that have resisted new treatments for ...

Casgevy sickle cell gene therapy is now FDA-approved for children as young as two, opening access for 5,500 more U.S. kids.